These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16126553)

  • 21. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Renin-angiotensin system modulation: instructions for use].
    Bellis A; Rozza F; Crispo S; Trimarco B
    G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.
    Garg S; Narula J; Marelli C; Cesario D
    Am J Cardiol; 2006 Mar; 97(6):921-5. PubMed ID: 16516603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G; Ostergren J; Struijker-Boudier H
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
    Ribeiro AB
    Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of cardiovascular damage: the role of renin-angiotensin system blockade.
    Probstfield JL; O'Brien KD
    Am J Cardiol; 2010 Jan; 105(1 Suppl):10A-20A. PubMed ID: 20102969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP; Maggioni A; Velazquez EJ
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system.
    Kurtz TW; Pravenec M
    Am J Hypertens; 2008 Aug; 21(8):852-9. PubMed ID: 18535538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
    Prisant LM
    Am J Med; 2008 Aug; 121(8 Suppl):S8-15. PubMed ID: 18638617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
    Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale for combining blockers of the renin-angiotensin system.
    Azizi M; Wuerzner G
    Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    Pfeffer MA
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S41-3. PubMed ID: 17199221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.